Home > Insider Trading > Filing (0001179110-13-004248)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
882095	Gilead Sciences Inc	GILD	Biological Products, (No Disgnostic Substances) (2836)	943047598

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1190578	C John Martin	Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404	Chairman And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2013-03-01	282,242	$7.63	4,288,674	No	4	M	Direct
Common Stock	Disposition	2013-03-01	214,707	$43.05	4,073,967	No	4	S	Direct
Common Stock	Disposition	2013-03-01	67,535	$43.43	4,006,432	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock option (right to buy)	Disposition	2013-03-01	282,242	$0.00	282,242	$7.63

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,540,178		2014-01-28	No	4	M	Direct

Footnotes

The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Sale prices reported for the transactions reported here range from $42.38 to $43.38. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Sale prices reported for the transactions reported here range from $43.39 to $43.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013.